WO1996024065A9 - Procedes de detection de procathepsines et leurs emplois - Google Patents
Procedes de detection de procathepsines et leurs emploisInfo
- Publication number
- WO1996024065A9 WO1996024065A9 PCT/US1996/001279 US9601279W WO9624065A9 WO 1996024065 A9 WO1996024065 A9 WO 1996024065A9 US 9601279 W US9601279 W US 9601279W WO 9624065 A9 WO9624065 A9 WO 9624065A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pro
- cathepsin
- antibody
- breast cancer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Definitions
- the pro-cathepsin may be a pro-cathepsin B, D or L.
- the bodily fluid may be plasma, serum, urine, saliva, lymphatic fluids, whole blood, nipple aspirates or other bodily fluids.
- the immobilized anti-cathepsin antibody may be a monoclonal or a polyclonal antibody.
- a suitable cathepsin binding agent may be used such as an enzyme inhibitor e.g. pepstatin.
- the unlabeled antibody may be a polyclonal antibody.
- the detectable antibody specific for the unlabeled antibody may be a horseradish peroxidase conjugate.
- the unlabeled antibody may be a polyclonal antibody.
- the detectable antibody specific for the unlabeled antibody may be a horseradish peroxidase conjugate.
- the prognosis may be a prognosis as to the likelihood of recurrence of cancer such as breast cancer. Alternatively, the prognosis may be the prognosis of relapse or of survival.
- CD cathepsin D
- MAP multiple antigenic peptide
- New Zealand white rabbits were immunized intra-nodally by injection into the popliteal lymph node (Dresser, 1986) . Animals were primed with 500 ⁇ g of MAP peptide in complete Freund's adjuvant and boosted 3 times with 250 ⁇ g in incomplete Freund's adjuvant.
- Pepstatin is a specific inhibitor of aspartic proteinases and has been used to affinity purify mature and pro-CD (Conner, 1989; Larsen, 1993) . Both forms bind strongly to pepstatin agarose at pH 3.5 and elute at pH 8.3. 50 ⁇ l of pepstatin agarose was incubated with plasma samples that had been adjusted to acidic pH. The beads were washed then the proteins eluted by the addition of pH 9 buffer and SDS-PAGE sample buffer. The entire sample was subjected to SDS-PAGE and immunoblotted using the mature CD monoclonal antibody. Whereas the previous immunoblots were limited to 0.25 ⁇ l of plasma, this procedure allowed for the analysis of 50 ⁇ l of each sample. This greatly improved the likelihood of detecting pro-CD while reducing nonspecific background bands.
Abstract
La présente invention concerne un procédé de pronostic concernant une patiente atteinte d'un cancer du sein. Ce procédé consiste en une détection quantitative de la procathepsine B, D ou L dans un échantillon de fluide biologique tel que le plasma, le sérum, l'urine, la salive, la lymphe, le sang total ou le fluide d'aspiration du mamelon. La détection de la procathepsine peut se faire en utilisant comme agent fixateur un agent liant la cathepsine. L'agent liant peut être des anticorps monoclonaux ou polyclonaux spécifiques de la procathepsine ou un inhibiteur d'enzyme tel que la pepstatine. Le pronostic peut porter sur la probabilité de reprise du cancer, de récidive ou de survie.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38287695A | 1995-02-03 | 1995-02-03 | |
| US08/382,876 | 1995-02-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996024065A1 WO1996024065A1 (fr) | 1996-08-08 |
| WO1996024065A9 true WO1996024065A9 (fr) | 1996-10-03 |
Family
ID=23510763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/001279 Ceased WO1996024065A1 (fr) | 1995-02-03 | 1996-02-02 | Procedes de detection de procathepsines et leurs emplois |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1996024065A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846739A (en) * | 1995-12-05 | 1998-12-08 | Wisconsin Alumni Research Foundation | Immunohistochemical detection assay for carcinoma proliferative status |
| WO2001069260A2 (fr) * | 2000-03-13 | 2001-09-20 | Research Foundation For Mental Hygiene, Inc. | Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein |
-
1996
- 1996-02-02 WO PCT/US1996/001279 patent/WO1996024065A1/fr not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5324634A (en) | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer | |
| EP0540573B2 (fr) | Analyse de l'antigene specifique de la prostate (psa) a l'etat libre et a l'etat formant complexe | |
| Diamandis et al. | Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications | |
| Diamandis et al. | Detection of prostate-specific antigen immunoreactivity in breast tumors | |
| CZ295854B6 (cs) | Způsob stanovení cPSA a testovací kit pro použití při tomto způsobu | |
| US20100151501A1 (en) | Forms of Prostate Specific Antigens and Methods for their Detection | |
| US6037138A (en) | Enzyme screen for breast cancer | |
| US6811995B1 (en) | Non-invasive enzyme screen for cancer | |
| US20070254317A1 (en) | Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate | |
| EP1175619B1 (fr) | Procede permettant de distinguer le cancer de la prostate de l'hyperplasie benigne de la prostate | |
| Matsumoto et al. | A highly sensitive enzyme-linked immunoassay for serum free prostate specific antigen (f-PSA) | |
| JAROSZ et al. | Elevated levels of pro-cathepsin-d in the plasma of breast-cancer patients | |
| US20040029200A1 (en) | Method and kits for the detection of renal cell carcinoma in a biological fluid of a patient | |
| WO1996024065A9 (fr) | Procedes de detection de procathepsines et leurs emplois | |
| WO1996024065A1 (fr) | Procedes de detection de procathepsines et leurs emplois | |
| US7288636B2 (en) | Forms of prostate specific antigens and methods for their detection | |
| Matsumoto et al. | ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen—assay-specific for complexed prostate-specific antigen | |
| US8481273B2 (en) | Perlecan fragments as biomarkers of bone stromal lysis | |
| Corey et al. | Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein | |
| WO2004099780A1 (fr) | Dosages immunologiques pour la detection de formes de recepteur d'urokinase | |
| US20060199230A1 (en) | Use of prostate specific antigen to predict drug response | |
| US20030153017A1 (en) | Antibodies which specifically recognize inactive PSA, and uses thereof | |
| US20030166036A1 (en) | Protease and an aminopeptidase associated with development of benign prostatic hyperplasia (BPH) | |
| AU6187801A (en) | Non-invasive enzyme screen for tissue remodelling-associated conditions | |
| PL188200B1 (pl) | Oznaczanie cPSA |